Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors
erlotinib
OSI-774-302
NCT00373425
EudraCT 2005-001747-29
Non-small cell lung cancer
Phase 3
 
November 2015

Powered by ideaPoint, Inc.